UPDATE : Thursday, August 22, 2019
상단여백
Japan gives further nod to Celltrion's breast cancer biosimilar
Celltrion Healthcare said that Japan's Ministry of Health, Labour and W...
by Lee Han-soo  |  2019-08-22 16:47
라인
Pharmicell submits new drug application for ovarian cancer treatment
Pharmicell said that it has filed an investigational new drug application t...
by Lee Han-soo  |  2019-08-19 13:10
라인
Stock exchange names Kolon Life Science as administrative issue
Kolon Life Science, once one of the most promising bio-stocks, has been dow...
by Lee Han-soo  |  2019-08-16 16:49
라인
Medipost’s stem cell therapy, cord blood bank show solid growth
Medipost’s stem cell therapy Cartistem for osteoarthritis and umbilical cor...
by Jeong Sae-im  |  2019-08-16 16:18
라인
CHA Biotech wins patent for placenta-derived mesenchymal stem cells
CHA Biotech said that it has obtained a patent for the use of placenta-deri...
by Lee Han-soo  |  2019-08-12 18:24
라인
Samsung BioLogics implants cell-culturing tech
Samsung BioLogics said that it has implanted a new cell-culturing technolog...
by Lee Han-soo  |  2019-08-12 16:05
라인
Injectable hydrogels developed to raise stem cell survival rate
Korean researchers have developed a technology of scaffolding stem cells wi...
by Song Soo-youn  |  2019-08-12 15:18
라인
HLB to seek pre-NDA meeting with FDA for rivoceranib
HLB said it would request for a pre-New Drug Application (NDA) meeting with...
by Jeong Sae-im  |  2019-08-06 15:43
라인
Roche, MSD, AstraZeneca: top 3 risers on NASDAQ biotech
Roche, MSD (Merck in the U.S.), and AstraZeneca achieved the most significa...
by Kim Yun-mi  |  2019-08-06 11:29
라인
Pharmicell submits investigational new drug application for prostate cancer treatment
Pharmicell said that it has filed an investigational new drug application t...
by Lee Han-soo  |  2019-08-05 17:59
라인
Sillajen’s trouble heralds fall of one of most prominent biotech firms
Shares of Sillajen continued to take a nosedive Monday after the biotech fi...
by Lee Han-soo  |  2019-08-05 16:55
라인
SillaJen remains confident about Pexa-Vec’s value, despite trial failure
SillaJen said Pexa-Vec, an oncolytic viral drug, still had significant pote...
by Jeong Sae-im  |  2019-08-05 14:49
라인
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension
With the likely suspension of SillaJen’s trial on its major anticancer pipe...
by Jeong Sae-im  |  2019-08-05 11:26
라인
Biotech shares tank amid SillaJen’s likely halt of Pexa-Vec trial
Local biotech shares went down altogether on Friday after SillaJen said it ...
by Jeong Sae-im  |  2019-08-02 15:45
라인
Eutilex pipelines are underrated: CEO
Eutilex CEO Kwon Byeong-se said he felt sorry for the recent fall of the co...
by Jeong Sae-im  |  2019-08-01 16:08
라인
Samsung BioLogics records Q2 operating loss
Samsung BioLogics logged an operating loss of 5.4 billion won ($13.1 millio...
by Lee Han-soo  |  2019-07-25 10:16
라인
Samsung Bioepis biosimilar sales in EU top $180 million in Q1
Samsung Bioepis’ sales in the European Union surpassed $180 million in the ...
by Lee Han-soo  |  2019-07-24 15:29
라인
Celltrion Healthcare joins Australia's pharma industry group
Celltrion Healthcare said that it has joined Australia's Generic and Bi...
by Lee Han-soo  |  2019-07-22 15:13
라인
Samsung BioLogics’ fate remains uncertain amid litigating ups and downs
The accounting fraud allegation involving Samsung BioLogics has been one of...
by Lee Han-soo  |  2019-07-19 18:16
라인
EU starts evaluating Samsung Bioepis’ sales application for Avastin biosimilar
Samsung Bioepis said that the European Medicines Agency (EMA) has started e...
by Lee Han-soo  |  2019-07-19 17:01
여백
여백
여백
Back to Top